A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-Centre Dose Ranging Study with the Beta-3 AGONist YM178 in Patients with Symptomatic Overactive Bladder (DRAGON).

Trial Profile

A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-Centre Dose Ranging Study with the Beta-3 AGONist YM178 in Patients with Symptomatic Overactive Bladder (DRAGON).

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2014

At a glance

  • Drugs Mirabegron (Primary) ; Tolterodine
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms DRAGON
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 09 Nov 2012 Planned number of patients changed from 770 to 1070 as reported by EudraCT.
    • 10 May 2011 Actual end date changed from 1 Mar 2007 to 23 Apr 2007 as reported by EudraCT (Denmark).
    • 10 May 2011 Planned end date (25 Jan 2007) added as reported by EudraCT (Spain, Czech Republic, Hungary, United Kingdom, Italy, Denmark, Germany, Sweden).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top